Your browser doesn't support javascript.
Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease.
Jeeyavudeen, Mohammad Sadiq; Chaudhari, Rahul; Pappachan, Joseph M; Fouda, Sherouk.
  • Jeeyavudeen MS; Department of Endocrinology and Metabolism, University Hospitals of Edinburgh, Edinburgh EH4 2XU, United Kingdom.
  • Chaudhari R; Department of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA 23298, United States.
  • Pappachan JM; Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, United Kingdom.
  • Fouda S; Faculty of Science, Manchester Metropolitan University, Manchester M15 6BH, United Kingdom.
World J Gastroenterol ; 29(3): 487-502, 2023 Jan 21.
Article in English | MEDLINE | ID: covidwho-2217140
ABSTRACT
People across the world are affected by the "coronavirus disease 2019 (COVID-19)", brought on by the "SARS-CoV type-2 coronavirus". Due to its high incidence in individuals with diabetes, metabolic syndrome, and metabolic-associated fatty liver disease (MAFLD), COVID-19 has gained much attention. The metabolic syndrome's hepatic manifestation, MAFLD, carries a significant risk of type-2-diabetes. The link between the above two conditions has also drawn increasing consideration since MAFLD is intricately linked to the obesity epidemic. Independent of the metabolic syndrome, MAFLD may impact the severity of the viral infections, including COVID-19 or may even be a risk factor. An important question is whether the present COVID-19 pandemic has been fueled by the obesity and MAFLD epidemics. Many liver markers are seen elevated in COVID-19. MAFLD patients with associated comorbid conditions like obesity, cardiovascular disease, renal disease, malignancy, hypertension, and old age are prone to develop severe disease. There is an urgent need for more studies to determine the link between the two conditions and whether it might account for racial differences in the mortality and morbidity rates linked to COVID-19. The role of innate and adaptive immunity alterations in MAFLD patients may influence the severity of COVID-19. This review investigates the implications of COVID-19 on liver injury and disease severity and vice-versa. We also addressed the severity of COVID-19 in patients with prior MAFLD and its potential implications and therapeutic administration in the clinical setting.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Metabolic Syndrome / Diabetes Mellitus, Type 2 / Non-alcoholic Fatty Liver Disease / COVID-19 Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: World J Gastroenterol Journal subject: Gastroenterology Year: 2023 Document Type: Article Affiliation country: Wjg.v29.i3.487

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Metabolic Syndrome / Diabetes Mellitus, Type 2 / Non-alcoholic Fatty Liver Disease / COVID-19 Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: World J Gastroenterol Journal subject: Gastroenterology Year: 2023 Document Type: Article Affiliation country: Wjg.v29.i3.487